These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 27207612)

  • 1. Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults.
    Ronson A; Tvito A; Rowe JM
    Curr Oncol Rep; 2016 Jun; 18(6):39. PubMed ID: 27207612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extramedullary relapse and discordant CD19 expression between bone marrow and extramedullary sites in relapsed acute lymphoblastic leukemia after blinatumomab treatment.
    Demosthenous C; Lalayanni C; Iskas M; Douka V; Pastelli N; Anagnostopoulos A
    Curr Probl Cancer; 2019 Jun; 43(3):222-227. PubMed ID: 29895435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia.
    DasGupta RK; Marini BL; Rudoni J; Perissinotti AJ
    J Oncol Pharm Pract; 2018 Sep; 24(6):453-467. PubMed ID: 28583018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New targeted therapies for relapsed pediatric acute lymphoblastic leukemia.
    Pierro J; Hogan LE; Bhatla T; Carroll WL
    Expert Rev Anticancer Ther; 2017 Aug; 17(8):725-736. PubMed ID: 28649891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful use of blinatumomab in a patient with acute lymphoblastic leukemia and severe hepatic dysfunction.
    Robinson AC; Marini BL; Pettit KM; Perissinotti AJ
    J Oncol Pharm Pract; 2020 Jan; 26(1):200-205. PubMed ID: 30760167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies.
    Kantarjian HM; Stein AS; Bargou RC; Grande Garcia C; Larson RA; Stelljes M; Gökbuget N; Zugmaier G; Benjamin JE; Zhang A; Jia C; Topp MS
    Cancer; 2016 Jul; 122(14):2178-85. PubMed ID: 27143254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Agents for refractory/relapsed acute lymphocytic leukemia in adults.
    Qian LR; Fu W; Shen JL
    Eur Rev Med Pharmacol Sci; 2014; 18(17):2465-74. PubMed ID: 25268091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Philadelphia chromosome-like alterations on efficacy and safety of blinatumomab in adults with relapsed/refractory acute lymphoblastic leukemia: A post hoc analysis from the phase 3 TOWER study.
    Jabbour E; Patel K; Jain N; Duose D; Luthra R; Short NJ; Zugmaier G; San Lucas A; Velasco K; Tran Q; Zaman F; Konopleva M; Kantarjian H
    Am J Hematol; 2021 Oct; 96(10):E379-E383. PubMed ID: 34161631
    [No Abstract]   [Full Text] [Related]  

  • 9. Feasibility of the Combination of Venetoclax and Asparaginase-based Chemotherapy for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.
    El-Cheikh J; Moukalled NM; El Darsa H; Massoud R; Kanj SS; Mahfouz R; Bazarbachi A
    Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):e441-e444. PubMed ID: 30166258
    [No Abstract]   [Full Text] [Related]  

  • 10. Structure, development, preclinical and clinical efficacy of blinatumomab in acute lymphoblastic leukemia.
    Bumma N; Papadantonakis N; Advani AS
    Future Oncol; 2015; 11(12):1729-39. PubMed ID: 26075441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel therapy for childhood acute lymphoblastic leukemia.
    Santiago R; Vairy S; Sinnett D; Krajinovic M; Bittencourt H
    Expert Opin Pharmacother; 2017 Aug; 18(11):1081-1099. PubMed ID: 28608730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
    Topp MS; Gökbuget N; Stein AS; Zugmaier G; O'Brien S; Bargou RC; Dombret H; Fielding AK; Heffner L; Larson RA; Neumann S; Foà R; Litzow M; Ribera JM; Rambaldi A; Schiller G; Brüggemann M; Horst HA; Holland C; Jia C; Maniar T; Huber B; Nagorsen D; Forman SJ; Kantarjian HM
    Lancet Oncol; 2015 Jan; 16(1):57-66. PubMed ID: 25524800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful reintroduction of blinatumomab in a patient with relapsed/refractory acute lymphoblastic leukemia following grade 4 cytokine release syndrome.
    Marini BL; Sun Y; Burke PW; Perissinotti AJ
    J Oncol Pharm Pract; 2018 Jan; 24(1):67-73. PubMed ID: 27799606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel targeted therapies in acute lymphoblastic leukemia.
    Portell CA; Advani AS
    Leuk Lymphoma; 2014 Apr; 55(4):737-48. PubMed ID: 23841506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.
    DeAngelo DJ
    Hematol Oncol Clin North Am; 2009 Oct; 23(5):1121-35, vii-viii. PubMed ID: 19825456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in the treatment of relapsed/refractory acute lymphoblastic leukemia: a case study compendium.
    Roboz GJ; Jabbour EJ; Faderl S; Douer D
    Clin Adv Hematol Oncol; 2014 Dec; 12(12 Suppl 20):8-18, 1. PubMed ID: 25768269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia.
    Dinner S; Lee D; Liedtke M
    Leuk Lymphoma; 2014 Aug; 55(8):1715-24. PubMed ID: 24251864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FLAG-liposomal doxorubicin (Myocet) regimen for refractory or relapsed acute leukemia pediatric patients.
    Quarello P; Berger M; Rivetti E; Galletto C; Masetti R; Manicone R; Barisone E; Pession A; Fagioli F
    J Pediatr Hematol Oncol; 2012 Apr; 34(3):208-16. PubMed ID: 22395219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy of Relapsed/Refractory Acute Lymphoblastic Leukemia Today and Tomorrow.
    Hrabovský Š; Folber F; Doubek M
    Klin Onkol; 2019; 32(2):90-96. PubMed ID: 30995847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Philadelphia chromosome-negative acute lymphoblastic leukemia: therapies under development.
    Parikh SA; Litzow MR
    Future Oncol; 2014 Nov; 10(14):2201-12. PubMed ID: 25471034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.